Dubai: BioAro, a pioneer in genomic research and technology, has officially launched PanOmiQ, a revolutionary software that will redefine the landscape of genomic analysis globally by providing real-time insights into the complexities of the human genome, the company said in a media release.
According the company, the product is set to transform healthcare worldwide with unparalleled speed, precision, and versatility. The global launch of PanOmiQ software took place at the Precision Medicine Expo on May 9, 2024, at Dubai World Trade Centre, UAE, and attended by representatives of the Consulate General of Canada, Dr Raees Tonse, Advisor to the Royal Family Office and Project Lead of Longevi-City in Ras Al Khaimah, George P. Patrinos, Professor, Division Head and Head of Laboratory, Editor-in-Chief of the Pharmacogenomics Journal, Harish Consul, Founder and CEO, Ocgrow Ventures, Divya Mishra, Bioinformatician, BioAro.
Genomics is the study of a person's genes (the genome), including interactions of those genes with each other and with the person's environment. Put simply, genomics is the study of an organism’s genome – its genetic material – and how that information is applied.
The global genomics market size was valued at $33.90 billion in 2023 and is poised to grow from $39.53 billion in 2024 to $157.47 billion by 2033, growing at a CAGR of 16.6 per cent in the forecast period (2024-2033), according to a research report by Biospace.
Despite rapid advances in sequencing technologies, accurately calling genetic variants present in an individual genome from billions of short, accurate sequence reads remains challenging. However, BioAro’s revolutionary and innovative software PanOmiQ is set to make it easy, according to the media release.
“PanOmiQ is an innovative software platform for a person’s all “Omics” analysis and reporting needs. It is an all-in-one solution for genetic analysis and report generation! PanOmiQ revolutionises the world of genetic analysis. BioAro’s cutting-edge platform enables comprehensive analysis of diverse omic data types, including genomics, transcriptomics, proteomics, and metabolomics, all within a single, seamless interface,” BioAro's, Founder and CEO Dr. Anmol S. Kapoor, said at the global launch of the game-changing innovation
“Our team at BioAro is committed to pushing the boundaries of genomic research and technology through real-time genomic testing and analysis to provide enhanced quality of life and health-span. With the launch of PanOmiQ, we are ushering in a new era of precision medicine, where every patient receives tailored treatments based on their unique genetic makeup.”
PanOmiQ is the world's fastest genomic analysis software to date. With its unified approach integrating primary, secondary, and tertiary analysis of genomic and metagenomic data, it enables healthcare specialists to decode DNA sequences in real time, empowering them to make informed decisions.
“Turnaround time in genomic analysis is critical, and this is where PanOmiQ comes in with its unmatched speed and accuracy. The proprietary AI-based platform also provides clinical annotations and helps better understand disease risk,” said Dr. Raja B. Singh, Chief Scientific Officer at BioAro.
While it once took 13 years to screen the human genome and now it typically takes around four weeks, PanOmiQ pushes the boundaries even further, completing the FastQ process in just seven hours, and in VC format in just 15 minutes. This remarkable efficiency not only streamlines processes but also reduces costs associated with ineffective treatments and prolonged recovery periods. By democratising access to genomic information, PanOmiQ aims to make precision medicine universally accessible and affordable, transcending geographical and socioeconomic barriers, says the company.
With the power of artificial intelligence, PanOmiQ helps identify rare diseases, health predispositions, and pharmacogenomic insights with unmatched speed and precision. Its ability to provide Pharmacogenomic analysis is a major advancement in tailoring treatment for optimal patient care.
Raees Tonse, Advisor to the Royal Family Office and Project Lead of Longevi-City project in Ras Al Khaimah, says, “PanOmiQ is a game-changer in precision healthcare, not only for this region but for the whole of mankind. It will change the future of human health and help people live longer.
“The global launch of PanOmiQ in the UAE will reinforce UAE’s position as a future hub of precision healthcare and medicine and will increase the lifespan of people in this part of the world.”
PanOmiQ's capabilities extend to microbial community analysis (metagenomics), medication tolerance assessment (pharmacogenomics), and soon, MultiOmics for proteins, metabolites, and the transcriptome. This approach enables the identification of biomarkers influenced by lifestyle, medications, and environmental factors, facilitating tailored healthcare interventions for multifactorial disorders like irritable bowel syndrome (IBS), rooted in dysbiosis, mental health issues, and lifestyle factors.
